openPR Logo
Press release

Naloxone Market To Cut Through Linear Growth

The Naloxone Market is expected to grow at an unstoppable rate In Upcoming Years. With environmental health being a matter of concern, everything - right from public transport networks, power supply, and storage of waste to monitoring the ecological balance is being taken up by IoT and AI. It could, thus, be inferred that with "smart cities" would come "smart end-user solutions" in the years to come.

Naloxone is an opioid antagonist medicine used in treatment of opioid overdose. Opioids are analgesics which are used for treatment of chronic pain but non-medical use of opioid is rapidly increasing. Opioids produces euphoria along with pain relieving action and hence opioid abuse is increasing worldwide. As per National Institute on Drug Abuse, approximately 130 people die every day as a result of opioid abuse in the United States alone.

Naloxone is used for the treatment of opioid overdose. The economic burden of prescription opioid misuse is more than US$ 78.5 billion per year in the United States, which represent significant economic burden and extent of opioid misuse. In 2017, more than 1.7 million people in the United States suffered from substance use disorder related to opioids and currently naloxone is the only effective medicine available for the treatment of the opioid overdose.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/27955

Increasing prevalence of opioids overdose expected to fuel the growth of naloxone market. Increasing incidence of opioid drug abuse in the developed as well as developing world expected to drive the growth of naloxone market. The use of opioids for chronic pain management is increasing worldwide and subsequently use of non-medical use of opioids is also increasing which in turn expected to drive the growth of naloxone market.

Increasing awareness about availability of naloxone for the treatment of the opioid overdose further expected to drive the growth of the market. Naloxone when administered shows early onset of the therapeutic action which helps to increase the patient compliance, driving the growth of naloxone market.

Easy to administer and measured dose formulations further increases patients as well as healthcare professionals compliance which in turn expected to drive the growth of the naloxone market.

Significant amount of the clinical trials undergoing for manufacturing novel dosage form for opioid abuse management expected to drive the growth of the naloxone market. Increasing efforts by healthcare professionals, advocacy groups Non-profit Organizations and government about opioid abuse and availability of the treatment expected to drive the growth of the naloxone market.

Request for Table of Content@ https://www.persistencemarketresearch.com/toc/27955

Market Segmentation

By route of administration
Injectables
Intramuscular or Subcutaneous
Intravenous
Nasal
Oral

By distribution channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

The global naloxone market is expected to be dominated by the North America due to higher incidence of opioid overdose in the region. Europe is expected to be second most lucrative naloxone market due to increasing awareness about the treatment for opioid overdose. Latin America expected to experience steady growth in naloxone market owing to gradually increasing use of naloxone for opioid overdose management in the region.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/27955

Asia-Pacific is emerging market in the global naloxone market due to increasing availability and regional manufacturers in the region. Middle East & Africa is the least lucrative market due to low market penetration of the product in the region. Globally increasing availability of the naloxone and awareness about the opioid overdose expected to be the major drivers in the market.

The key market players in the global naloxone market are: ADAPT Pharma, Inc., kaleo, Inc., Amphastar Pharmaceuticals, Inc., Pfizer Inc., Sandoz, SG Pharma Pvt. Ltd., Troikaa Pharmaceuticals Ltd., Samarth Life Sciences Pvt. Ltd., Somerset Therapeutics LLC, and others.

Access Related Reports-

Life Sciences Aggregate-Spending Market: https://www.persistencemarketresearch.com/market-research/life-sciences-aggregate-spending-sunshine-law-tracking-and-reporting-market.asp

Single Domain Antibody Platforms Market: https://www.persistencemarketresearch.com/market-research/single-domain-antibody-platforms-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Naloxone Market To Cut Through Linear Growth here

News-ID: 2599035 • Views: …

More Releases from Persistence Market Research

Electrified Aircraft Propulsion Market to Reach US$ 26.5 bn by 2033 Driven by Sustainable Aviation Demand
Electrified Aircraft Propulsion Market to Reach US$ 26.5 bn by 2033 Driven by Su …
The global electrified aircraft propulsion market covers propulsion architectures and associated systems that use electrical power to drive or assist aircraft movement. Persistence Market Research values the market at US$ 9.8 billion in 2026 and projects it to reach US$ 26.5 billion by 2033, registering a compound annual growth rate (CAGR) of 15.3% during 2026-2033. The commercial challenge is converting electrical technologies into certified aircraft systems at acceptable lifecycle cost. Operators…
Dill Seed Market to Reach US$1.2 Billion by 2033 Driven by Rising Food Industry Demand
Dill Seed Market to Reach US$1.2 Billion by 2033 Driven by Rising Food Industry …
Persistence Market Research values the dill seed market at US$0.9 billion in 2026 and projects US$1.2 billion by 2033, a 4.3% CAGR during 2026-2033. It covers Whole Dill Seed, Ground Dill Seed, and Dill Seed Oil for Food and Beverages, Pharmaceuticals, and Personal Care across six global regions. Dill seed is the aromatic seed of the dill plant, traded whole, milled, or processed into oil. Demand spans established culinary uses…
Pet Food Flavor Market to Reach US$6.0 Bn by 2033 Driven by Rising Pet Humanization Trends
Pet Food Flavor Market to Reach US$6.0 Bn by 2033 Driven by Rising Pet Humanizat …
The global pet food flavor market is estimated to reach US$4.0 billion in 2026 and is projected to attain US$6.0 billion by 2033, expanding at a CAGR of 5.9% during 2026-2033, according to Persistence Market Research. The market covers flavor solutions used to improve the sensory appeal and palatability of pet food products. Its scope includes natural flavors and artificial flavors, serving dogs, cats, birds, and fish across global markets.…
Pea Fiber Market to Reach US$28.3 Bn by 2033 Driven by Clean-Label Plant-Based Ingredients
Pea Fiber Market to Reach US$28.3 Bn by 2033 Driven by Clean-Label Plant-Based I …
Pea fiber is dietary fiber obtained from yellow peas, green peas and field peas, used for water binding, moisture retention and texture control. Persistence Market Research estimates the global market at US$17.3 billion in 2026 and projects US$28.3 billion by 2033, a 7.3% CAGR over 2026-2033. The report does not specify a separate base year. The central commercial challenge is delivering fiber enrichment without compromising sensory quality or manufacturing efficiency.…

All 5 Releases


More Releases for Pharma

Schizophrenia Market Forecast 2036: Rising Demand, Novel Therapies, and Commerci …
The Key Schizophrenia Companies in the market include - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Otsuka Pharmaceutical, Lyndra Therapeutics, Neurocrine Biosciences, and others. (Albany, New York) - October 19, 2026: DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2036" provides a comprehensive analysis…
Schizophrenia Market Gains Momentum with Expanding Pipeline and Investment Poten …
The Key Schizophrenia Companies in the market include - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Acadia Pharmaceuticals, Boehringer Ingelheim, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others. DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2036" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed…
Schizophrenia Market: Expanding Revenue Landscape to 2034 - DelveInsight | Teva …
The Key Schizophrenia Companies in the market inlclude - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, and others. DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…